Initial dose reduction of enzalutamide does not decrease the incidence of adverse events in castration-resistant prostate cancer.

<h4>Background</h4>There was no clear evidence whether the initial dose of enzalutamide affects the incidence of adverse events (AEs), and oncological outcome in patients with castration-resistant prostate cancer (CRPC).<h4>Methods</h4>The clinical charts of 233 patients with...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Shunsuke Tsuzuki, Shotaro Nakanishi, Mitsuyoshi Tamaki, Takuma Oshiro, Jun Miki, Hiroki Yamada, Tatsuya Shimomura, Takahiro Kimura, Nozomu Furuta, Seiichi Saito, Shin Egawa
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/b374a1b5ca054b888c6dc81210d59f89
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:b374a1b5ca054b888c6dc81210d59f89
record_format	dspace
spelling	oai:doaj.org-article:b374a1b5ca054b888c6dc81210d59f892021-12-02T20:17:22ZInitial dose reduction of enzalutamide does not decrease the incidence of adverse events in castration-resistant prostate cancer.1932-620310.1371/journal.pone.0258160https://doaj.org/article/b374a1b5ca054b888c6dc81210d59f892021-01-01T00:00:00Zhttps://doi.org/10.1371/journal.pone.0258160https://doaj.org/toc/1932-6203<h4>Background</h4>There was no clear evidence whether the initial dose of enzalutamide affects the incidence of adverse events (AEs), and oncological outcome in patients with castration-resistant prostate cancer (CRPC).<h4>Methods</h4>The clinical charts of 233 patients with CRPC treated with enzalutamide were reviewed retrospectively. After 1:3 propensity score matching (PSM), 124 patients were divided into a reduced dose group and a standard dose group, and the prostate specific antigen (PSA) response and the incidence of AEs were compared.<h4>Results</h4>190 patients with CRPC initiated with standard dose enzalutamide were younger and better performance status compared with 43 patients beginning with reduced dose. After PSM, the baseline characteristics were not different between the standard and the reduced dose group. In the PSM cohort, the PSA response rate was significantly lower in the reduced dose group than in the standard dose group (-66.3% and -87.4%, p = 0.02). The incidence rates of AEs were not statistically different between the groups (22.6% and 34.4%, respectively, p = 0.24).<h4>Conclusion</h4>Initiating treatment with a reduced dose of enzalutamide did not significantly decrease the incidence rate of AEs, and it showed poorer PSA response rate. There is no clear rationale for treating with a reduced initial dose of enzalutamide to reduce the incidence of AEs.Shunsuke TsuzukiShotaro NakanishiMitsuyoshi TamakiTakuma OshiroJun MikiHiroki YamadaTatsuya ShimomuraTakahiro KimuraNozomu FurutaSeiichi SaitoShin EgawaPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 16, Iss 10, p e0258160 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Shunsuke Tsuzuki Shotaro Nakanishi Mitsuyoshi Tamaki Takuma Oshiro Jun Miki Hiroki Yamada Tatsuya Shimomura Takahiro Kimura Nozomu Furuta Seiichi Saito Shin Egawa Initial dose reduction of enzalutamide does not decrease the incidence of adverse events in castration-resistant prostate cancer.
description	<h4>Background</h4>There was no clear evidence whether the initial dose of enzalutamide affects the incidence of adverse events (AEs), and oncological outcome in patients with castration-resistant prostate cancer (CRPC).<h4>Methods</h4>The clinical charts of 233 patients with CRPC treated with enzalutamide were reviewed retrospectively. After 1:3 propensity score matching (PSM), 124 patients were divided into a reduced dose group and a standard dose group, and the prostate specific antigen (PSA) response and the incidence of AEs were compared.<h4>Results</h4>190 patients with CRPC initiated with standard dose enzalutamide were younger and better performance status compared with 43 patients beginning with reduced dose. After PSM, the baseline characteristics were not different between the standard and the reduced dose group. In the PSM cohort, the PSA response rate was significantly lower in the reduced dose group than in the standard dose group (-66.3% and -87.4%, p = 0.02). The incidence rates of AEs were not statistically different between the groups (22.6% and 34.4%, respectively, p = 0.24).<h4>Conclusion</h4>Initiating treatment with a reduced dose of enzalutamide did not significantly decrease the incidence rate of AEs, and it showed poorer PSA response rate. There is no clear rationale for treating with a reduced initial dose of enzalutamide to reduce the incidence of AEs.
format	article
author	Shunsuke Tsuzuki Shotaro Nakanishi Mitsuyoshi Tamaki Takuma Oshiro Jun Miki Hiroki Yamada Tatsuya Shimomura Takahiro Kimura Nozomu Furuta Seiichi Saito Shin Egawa
author_facet	Shunsuke Tsuzuki Shotaro Nakanishi Mitsuyoshi Tamaki Takuma Oshiro Jun Miki Hiroki Yamada Tatsuya Shimomura Takahiro Kimura Nozomu Furuta Seiichi Saito Shin Egawa
author_sort	Shunsuke Tsuzuki
title	Initial dose reduction of enzalutamide does not decrease the incidence of adverse events in castration-resistant prostate cancer.
title_short	Initial dose reduction of enzalutamide does not decrease the incidence of adverse events in castration-resistant prostate cancer.
title_full	Initial dose reduction of enzalutamide does not decrease the incidence of adverse events in castration-resistant prostate cancer.
title_fullStr	Initial dose reduction of enzalutamide does not decrease the incidence of adverse events in castration-resistant prostate cancer.
title_full_unstemmed	Initial dose reduction of enzalutamide does not decrease the incidence of adverse events in castration-resistant prostate cancer.
title_sort	initial dose reduction of enzalutamide does not decrease the incidence of adverse events in castration-resistant prostate cancer.
publisher	Public Library of Science (PLoS)
publishDate	2021
url	https://doaj.org/article/b374a1b5ca054b888c6dc81210d59f89
work_keys_str_mv	AT shunsuketsuzuki initialdosereductionofenzalutamidedoesnotdecreasetheincidenceofadverseeventsincastrationresistantprostatecancer AT shotaronakanishi initialdosereductionofenzalutamidedoesnotdecreasetheincidenceofadverseeventsincastrationresistantprostatecancer AT mitsuyoshitamaki initialdosereductionofenzalutamidedoesnotdecreasetheincidenceofadverseeventsincastrationresistantprostatecancer AT takumaoshiro initialdosereductionofenzalutamidedoesnotdecreasetheincidenceofadverseeventsincastrationresistantprostatecancer AT junmiki initialdosereductionofenzalutamidedoesnotdecreasetheincidenceofadverseeventsincastrationresistantprostatecancer AT hirokiyamada initialdosereductionofenzalutamidedoesnotdecreasetheincidenceofadverseeventsincastrationresistantprostatecancer AT tatsuyashimomura initialdosereductionofenzalutamidedoesnotdecreasetheincidenceofadverseeventsincastrationresistantprostatecancer AT takahirokimura initialdosereductionofenzalutamidedoesnotdecreasetheincidenceofadverseeventsincastrationresistantprostatecancer AT nozomufuruta initialdosereductionofenzalutamidedoesnotdecreasetheincidenceofadverseeventsincastrationresistantprostatecancer AT seiichisaito initialdosereductionofenzalutamidedoesnotdecreasetheincidenceofadverseeventsincastrationresistantprostatecancer AT shinegawa initialdosereductionofenzalutamidedoesnotdecreasetheincidenceofadverseeventsincastrationresistantprostatecancer
_version_	1718374425421676544

Initial dose reduction of enzalutamide does not decrease the incidence of adverse events in castration-resistant prostate cancer.

Ejemplares similares